Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Zevra Therapeutics (ZVRA) over the last 5 years, with Q3 2025 value amounting to $11.0 million.

  • Zevra Therapeutics' Treasury Shares changed 0.0% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $11.0 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2024, Zevra Therapeutics' Treasury Shares is $1.8 million, which was up 17612.29% from $665739.0 recorded in Q4 2023.
  • Over the past 5 years, Zevra Therapeutics' Treasury Shares peaked at $1.8 million during Q4 2024, and registered a low of $320161.0 during Q4 2021.
  • For the 4-year period, Zevra Therapeutics' Treasury Shares averaged around $964077.1, with its median value being $787846.0 (2022).
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 16780.38% in 2022, then changed by 0.0% in 2024.
  • Over the past 5 years, Zevra Therapeutics' Treasury Shares (Quarter) stood at $2.8 million in 2021, then surged by 167.8% to $7.5 million in 2022, then surged by 45.74% to $11.0 million in 2023, then changed by 0.0% to $11.0 million in 2024, then changed by 0.0% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $11.0 million for Q2 2025, and $11.0 million during Q1 2025.